Rhumbline Advisers Purchases 11,010 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Rhumbline Advisers increased its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 14.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 88,781 shares of the company’s stock after buying an additional 11,010 shares during the period. Rhumbline Advisers owned 0.14% of Nurix Therapeutics worth $1,853,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Quest Partners LLC acquired a new position in shares of Nurix Therapeutics in the 4th quarter valued at approximately $59,000. GAMMA Investing LLC raised its holdings in Nurix Therapeutics by 299.8% during the second quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares during the last quarter. EntryPoint Capital LLC acquired a new position in Nurix Therapeutics during the first quarter worth $123,000. China Universal Asset Management Co. Ltd. raised its holdings in Nurix Therapeutics by 67.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,404 shares of the company’s stock worth $138,000 after buying an additional 3,793 shares during the last quarter. Finally, Jump Financial LLC purchased a new stake in shares of Nurix Therapeutics in the fourth quarter valued at about $158,000.

Nurix Therapeutics Stock Performance

Shares of NASDAQ:NRIX opened at $25.62 on Friday. Nurix Therapeutics, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $26.31. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -8.77 and a beta of 2.23. The business has a 50-day simple moving average of $22.96 and a two-hundred day simple moving average of $18.28.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Thursday, July 11th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.08). Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. The firm had revenue of $12.09 million during the quarter, compared to analysts’ expectations of $19.35 million. As a group, research analysts predict that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Truist Financial began coverage on shares of Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price objective for the company. Barclays lifted their target price on shares of Nurix Therapeutics from $20.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, July 15th. JPMorgan Chase & Co. lifted their target price on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, July 15th. Needham & Company LLC cut their price target on shares of Nurix Therapeutics from $31.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, July 12th. Finally, Piper Sandler restated an “overweight” rating and set a $35.00 target price on shares of Nurix Therapeutics in a report on Wednesday, June 5th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at $781,870.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CFO Houte Hans Van sold 20,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at $781,870.44. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Christine Ring sold 9,870 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.01, for a total transaction of $246,848.70. Following the completion of the transaction, the insider now directly owns 24,592 shares of the company’s stock, valued at $615,045.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,815 shares of company stock valued at $1,416,751. 7.20% of the stock is owned by corporate insiders.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.